IN BRIEF: RTW Biotech's Rocket Pharmaceuticals makes Danon progress
RTW Biotech Opportunities Ltd - New York-based investment firm focused on the life sciences sector - Notes announcement by its largest portfolio company position, Rocket Pharmaceuticals, Inc. Says Rocket has reached alignment with the US Food and Drug Administration on the trial design for its phase two trial of RP-A501 for Danon disease, a fatal inherited cardiomyopathy for which there is currently no cure. Read More